Balance Sheet StrengthA strong equity base and low leverage provide durable financial flexibility to fund R&D, absorb setbacks and negotiate partnerships without immediate refinancing. This capital structure supports long-term product development and commercialization even if cash conversion cycles vary.

High And Improving MarginsSustainably high gross margins and improving EBIT/EBITDA margins indicate efficient production and cost control, giving pricing power and the ability to reinvest in innovation. Durable margin improvement supports profitability as revenue scales and aids funding of strategic projects.

Niche Specialization And Multiple Revenue StreamsA focused myopia/eye-health specialization plus mixed revenue channels (product sales, licensing, collaboration fees) creates multiple monetization levers. This structured model can sustain recurring and milestone-based income and support long-term IP monetization strategies.

Bears Say

Negative Operating Cash FlowPersistent negative operating and free cash flow strains liquidity and raises reliance on external financing or equity raises. That can limit capital available for marketing, regulatory approvals and scale-up, slowing durable commercialization and increasing financing risk.

Volatile/declining Reported GrowthSteep negative revenue and EPS growth reflect volatile commercialization and profitability execution. Such swings hinder predictability for investment in R&D and distribution, complicate long-term planning, and can weaken negotiating leverage with partners and payors.

Very Small WorkforceA tiny employee base limits internal R&D throughput, regulatory, sales and commercial capabilities, increasing dependence on external partners. That constrains the company’s ability to scale operations and execute multiple concurrent product rollouts reliably over months.

Tsubota Laboratory Incorporated News

Tsubota Laboratory Swings to Heavy Loss as Revenue Plunges, Forecasts Deep Full-Year Deficit

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory reported a sharp deterioration in non-consolidated...

4d ago

4890

Tsubota Laboratory’s Interim Financial Results Highlight Sustainable Growth Strategy

Tsubota Laboratory Incorporated ( ($JP:4890) ) has provided an announcement. Tsubota Laboratory Incorporated has announced its interim financial...

3M ago

4890

Tsubota Laboratory Reports Significant Revenue Decline and Net Loss

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory Incorporated reported a significant decline in...

3M ago

4890

Tsubota Laboratory Reports First Quarter Losses Amidst Sales Decline

An update from Tsubota Laboratory Incorporated ( ($JP:4890) ) is now available. Tsubota Laboratory Incorporated reported a decrease...

6M ago

4890

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

The latest announcement is out from Tsubota Laboratory Incorporated ( ($JP:4890) ). Tsubota Laboratory, Inc. reported significant financial...

9M ago

4890

Tsubota Laboratory’s Impressive Financial Turnaround in 2024

Tsubota Laboratory Incorporated (JP:4890) has released an update. Tsubota Laboratory, Inc. reports a significant increase in net sales...

1y ago

4890

4890 FAQ

What was Tsubota Laboratory Incorporated’s price range in the past 12 months?

Tsubota Laboratory Incorporated lowest stock price was ¥261.00 and its highest was ¥460.00 in the past 12 months.

What is Tsubota Laboratory Incorporated’s market cap?

Tsubota Laboratory Incorporated’s market cap is ¥7.04B.

When is Tsubota Laboratory Incorporated’s upcoming earnings report date?

Tsubota Laboratory Incorporated’s upcoming earnings report date is May 18, 2026 which is in 90 days.

How were Tsubota Laboratory Incorporated’s earnings last quarter?

Tsubota Laboratory Incorporated released its earnings results on Feb 13, 2026. The company reported -¥7.22 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.22.

Is Tsubota Laboratory Incorporated overvalued?

According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tsubota Laboratory Incorporated pay dividends?

Tsubota Laboratory Incorporated does not currently pay dividends.

What is Tsubota Laboratory Incorporated’s EPS estimate?

Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tsubota Laboratory Incorporated have?

Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.

What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?

Tsubota Laboratory Incorporated reported an EPS of -¥7.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.534%.

Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?

Currently, no hedge funds are holding shares in JP:4890

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.